-+ 0.00%
-+ 0.00%
-+ 0.00%

Evaxion data show AI-Immunology platform designs glioblastoma vaccine targets, AACR presentation pending

PUBT·04/17/2026 19:01:05
Listen to the news
Evaxion data show AI-Immunology platform designs glioblastoma vaccine targets, AACR presentation pending
  • Evaxion reported new data supporting use of its AI-Immunology platform to design personalized cancer vaccines for glioblastoma.
  • Results will be presented April 22, 2026, at AACR Annual Meeting in San Diego.
  • Analysis with Duke University School of Medicine identified endogenous retrovirus-derived tumor targets as potential additions to glioblastoma vaccines.
  • Findings also indicated mutation-derived targets suitable for inclusion in vaccines in most patients.
  • Evaxion positioned data as proof-of-concept that its platform can broaden target selection in low-mutation tumors, potentially improving vaccine effectiveness.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604171500OMX_____CNEWS_EN_GNW1001176430_en) on April 17, 2026, and is solely responsible for the information contained therein.